JP2010500993A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500993A5
JP2010500993A5 JP2009524665A JP2009524665A JP2010500993A5 JP 2010500993 A5 JP2010500993 A5 JP 2010500993A5 JP 2009524665 A JP2009524665 A JP 2009524665A JP 2009524665 A JP2009524665 A JP 2009524665A JP 2010500993 A5 JP2010500993 A5 JP 2010500993A5
Authority
JP
Japan
Prior art keywords
optionally substituted
triazole
mercapto
phenyl
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009524665A
Other languages
English (en)
Japanese (ja)
Other versions
JP5480623B2 (ja
JP2010500993A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/017996 external-priority patent/WO2008021364A2/en
Publication of JP2010500993A publication Critical patent/JP2010500993A/ja
Publication of JP2010500993A5 publication Critical patent/JP2010500993A5/ja
Application granted granted Critical
Publication of JP5480623B2 publication Critical patent/JP5480623B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009524665A 2006-08-17 2007-08-14 Hsp90活性を調節するトリアゾール化合物 Expired - Fee Related JP5480623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83830606P 2006-08-17 2006-08-17
US60/838,306 2006-08-17
PCT/US2007/017996 WO2008021364A2 (en) 2006-08-17 2007-08-14 Triazole compounds that modulate hsp90 activity

Publications (3)

Publication Number Publication Date
JP2010500993A JP2010500993A (ja) 2010-01-14
JP2010500993A5 true JP2010500993A5 (enExample) 2010-10-21
JP5480623B2 JP5480623B2 (ja) 2014-04-23

Family

ID=38924466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524665A Expired - Fee Related JP5480623B2 (ja) 2006-08-17 2007-08-14 Hsp90活性を調節するトリアゾール化合物

Country Status (6)

Country Link
US (1) US8188075B2 (enExample)
EP (1) EP2054059A2 (enExample)
JP (1) JP5480623B2 (enExample)
AU (1) AU2007284537B2 (enExample)
CA (1) CA2659425C (enExample)
WO (1) WO2008021364A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01498B (me) * 2004-11-18 2014-04-20 Synta Pharmaceuticals Corp Jedinjenja triazola koja modulišu aktivnost hsp90
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Hsp90活性を調節するピラゾール化合物
EP1928846B1 (en) 2005-08-18 2014-06-04 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
WO2007139955A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AU2007267859B2 (en) 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
US20080027047A1 (en) * 2006-05-25 2008-01-31 Weiwen Ying Compounds that modulate HSP90 activity and methods for identifying same
WO2007140002A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
EP2034995A2 (en) 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Method for treating proliferative disorders associated with protooncogene products
US20110046125A1 (en) * 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
CA2677481C (en) * 2007-02-08 2015-07-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2008153730A2 (en) * 2007-05-25 2008-12-18 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-met
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
WO2009139916A1 (en) * 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
US8648071B2 (en) 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
PT2328893E (pt) 2008-08-08 2013-06-27 Synta Pharmaceuticals Corp Compostos de triazol que modulam a actividade da hsp90
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
EP2560641A2 (en) * 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
JP2014520808A (ja) 2011-07-07 2014-08-25 シンタ ファーマシューティカルズ コーポレーション Hsp90阻害化合物を用いた癌の治療
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法
EP2776025A1 (en) 2011-11-02 2014-09-17 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
EP2780010A1 (en) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
NZ737004A (en) 2015-05-20 2022-10-28 Amgen Inc Triazole agonists of the apj receptor
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
JP7458406B2 (ja) 2018-12-21 2024-03-29 セルジーン コーポレーション Ripk2のチエノピリジン阻害剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089367A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US20060235034A1 (en) * 2004-11-01 2006-10-19 Nouri Neamati Novel compounds for treatment of cancer and disorders associated with angiogenesis function
ME01498B (me) * 2004-11-18 2014-04-20 Synta Pharmaceuticals Corp Jedinjenja triazola koja modulišu aktivnost hsp90
DE102005007304A1 (de) * 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
CN101160291B (zh) * 2005-03-09 2012-09-05 日本化药株式会社 作为hsp90抑制剂的三唑衍生物
EP1928846B1 (en) * 2005-08-18 2014-06-04 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102006023337A1 (de) * 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
EP2034995A2 (en) * 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Method for treating proliferative disorders associated with protooncogene products
WO2007139955A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20080027047A1 (en) * 2006-05-25 2008-01-31 Weiwen Ying Compounds that modulate HSP90 activity and methods for identifying same
WO2007140002A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
AU2007267859B2 (en) 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
TW200806637A (en) * 2006-05-25 2008-02-01 Synta Pharmaceuticals Corp Synthesis of triazole compounds that modulate HSP90 activity

Similar Documents

Publication Publication Date Title
JP2010500993A5 (enExample)
JP2008520702A5 (enExample)
JP2009538320A5 (enExample)
RU2612958C2 (ru) 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
JP2009538322A5 (enExample)
JP2009538321A5 (enExample)
JP2013508378A5 (enExample)
HRP20130095T1 (hr) Spojevi triazola koji moduliraju aktivnost hsp90
US7399759B2 (en) 1, 3-benzothiazinone derivatives and use thereof
JP2010536753A5 (enExample)
JP2010518085A5 (enExample)
US6620825B1 (en) Adenosine A3 receptor antagonists
AU2012200157B2 (en) Method for treating proliferative disorders associated with protooncogene products
AU2007267843A1 (en) Method for treating proliferative disorders associated with protooncogene products
JP2020527560A5 (enExample)
JP2007510689A5 (enExample)
JP2008500992A5 (enExample)
ZA200305619B (en) Substituted triazole diamine derivatives as kinase inhibitors.
JP2014526500A5 (enExample)
CA2451678A1 (en) Azaindoles
CA2456817A1 (en) Alkyne-aryl-naphthyridin-4 (1h)-one derivatives as type iv phosphodiesterase inhibitor
WO2011146801A1 (en) Formulation and dosing of hsp90 inhibitory compounds
RU2010119487A (ru) Пиримидилиндолиновое соединение
JP2010540602A5 (enExample)
AU2009259021A1 (en) 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors